

CS/HB 1345

2021

1                   A bill to be entitled  
2                   An act relating to pharmaceutical products containing  
3                   cannabis; amending s. 893.03, F.S.; excluding from  
4                   Schedule I cannabis if it is contained within a  
5                   pharmaceutical product approved by the United States  
6                   Food and Drug Administration; removing provisions  
7                   concerning the scheduling of certain drug products  
8                   containing cannabidiol; amending s. 893.02, F.S.;  
9                   conforming provisions to changes made by the act;  
10                  providing an effective date.

11  
12 Be It Enacted by the Legislature of the State of Florida:

13  
14                  Section 1. Paragraph (c) of subsection (1) and paragraph  
15                  (d) of subsection (5) of section 893.03, Florida Statutes, are  
16                  amended to read:

17                  893.03 Standards and schedules.—The substances enumerated  
18                  in this section are controlled by this chapter. The controlled  
19                  substances listed or to be listed in Schedules I, II, III, IV,  
20                  and V are included by whatever official, common, usual,  
21                  chemical, trade name, or class designated. The provisions of  
22                  this section shall not be construed to include within any of the  
23                  schedules contained in this section any excluded drugs listed  
24                  within the purview of 21 C.F.R. s. 1308.22, styled "Excluded  
25                  Substances"; 21 C.F.R. s. 1308.24, styled "Exempt Chemical

CS/HB 1345

2021

26 Preparations"; 21 C.F.R. s. 1308.32, styled "Exempted  
27 Prescription Products"; or 21 C.F.R. s. 1308.34, styled "Exempt  
28 Anabolic Steroid Products."

29 (1) SCHEDULE I.—A substance in Schedule I has a high  
30 potential for abuse and has no currently accepted medical use in  
31 treatment in the United States and in its use under medical  
32 supervision does not meet accepted safety standards. The  
33 following substances are controlled in Schedule I:

34 (c) Unless specifically excepted or unless listed in  
35 another schedule, any material, compound, mixture, or  
36 preparation that contains any quantity of the following  
37 hallucinogenic substances or that contains any of their salts,  
38 isomers, including optical, positional, or geometric isomers,  
39 homologues, nitrogen-heterocyclic analogs, esters, ethers, and  
40 salts of isomers, homologues, nitrogen-heterocyclic analogs,  
41 esters, or ethers, if the existence of such salts, isomers, and  
42 salts of isomers is possible within the specific chemical  
43 designation or class description:

- 44 1. Alpha-Ethyltryptamine.
- 45 2. 4-Methylaminorex (2-Amino-4-methyl-5-phenyl-2-  
46 oxazoline).
- 47 3. Aminorex (2-Amino-5-phenyl-2-oxazoline).
- 48 4. DOB (4-Bromo-2,5-dimethoxyamphetamine).
- 49 5. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
- 50 6. Bufotenine.

CS/HB 1345

2021

- 51       7. Cannabis, except if it is contained within a  
52       pharmaceutical product approved by the United States Food and  
53       Drug Administration.
- 54       8. Cathinone.
- 55       9. DET (Diethyltryptamine).
- 56       10. 2,5-Dimethoxyamphetamine.
- 57       11. DOET (4-Ethyl-2,5-Dimethoxyamphetamine).
- 58       12. DMT (Dimethyltryptamine).
- 59       13. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine  
60 analog of phencyclidine).
- 61       14. JB-318 (N-Ethyl-3-piperidyl benzilate).
- 62       15. N-Ethylamphetamine.
- 63       16. Fenethylline.
- 64       17. 3,4-Methylenedioxy-N-hydroxyamphetamine.
- 65       18. Ibogaine.
- 66       19. LSD (Lysergic acid diethylamide).
- 67       20. Mescaline.
- 68       21. Methcathinone.
- 69       22. 5-Methoxy-3,4-methylenedioxyamphetamine.
- 70       23. PMA (4-Methoxyamphetamine).
- 71       24. PMMA (4-Methoxymethamphetamine).
- 72       25. DOM (4-Methyl-2,5-dimethoxyamphetamine).
- 73       26. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
- 74       27. MDA (3,4-Methylenedioxyamphetamine).
- 75       28. JB-336 (N-Methyl-3-piperidyl benzilate).

CS/HB 1345

2021

- 76        29. N,N-Dimethylamphetamine.
- 77        30. Parahexyl.
- 78        31. Peyote.
- 79        32. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine  
80        analog of phencyclidine).
- 81        33. Psilocybin.
- 82        34. Psilocyn.
- 83        35. *Salvia divinorum*, except for any drug product approved  
84        by the United States Food and Drug Administration which contains  
85        *Salvia divinorum* or its isomers, esters, ethers, salts, and  
86        salts of isomers, esters, and ethers, if the existence of such  
87        isomers, esters, ethers, and salts is possible within the  
88        specific chemical designation.
- 89        36. Salvinorin A, except for any drug product approved by  
90        the United States Food and Drug Administration which contains  
91        Salvinorin A or its isomers, esters, ethers, salts, and salts of  
92        isomers, esters, and ethers, if the existence of such isomers,  
93        esters, ethers, and salts is possible within the specific  
94        chemical designation.
- 95        37. Xylazine.
- 96        38. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)  
97        (Thiophene analog of phencyclidine).
- 98        39. 3,4,5-Trimethoxyamphetamine.
- 99        40. Methylone (3,4-Methylenedioxymethcathinone).
- 100       41. MDPV (3,4-Methylenedioxypyrovalerone).

CS/HB 1345

2021

- 101        42. Methylmethcathinone.
- 102        43. Methoxymethcathinone.
- 103        44. Fluoromethcathinone.
- 104        45. Methylethcathinone.
- 105        46. CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2-yl)phenol) and its dimethyloctyl (C8) homologue.
- 106        47. HU-210 [(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol].
- 107        48. JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
- 108        49. JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
- 109        50. JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole).
- 110        51. BZP (Benzylpiperazine).
- 111        52. Fluorophenylpiperazine.
- 112        53. Methylphenylpiperazine.
- 113        54. Chlorophenylpiperazine.
- 114        55. Methoxyphenylpiperazine.
- 115        56. DBZP (1,4-Dibenzylpiperazine).
- 116        57. TFMPP (Trifluoromethylphenylpiperazine).
- 117        58. MBDB (Methylbenzodioxolylbutanamine) or (3,4-Methylenedioxy-N-methylbutanamine).
- 118        59. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
- 119        60. 5-Hydroxy-N-methyltryptamine.
- 120        61. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).

- 126        62. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine) .  
127        63. Methyltryptamine.  
128        64. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) .  
129        65. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine) .  
130        66. Tyramine (4-Hydroxyphenethylamine) .  
131        67. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine) .  
132        68. DiPT (N,N-Diisopropyltryptamine) .  
133        69. DPT (N,N-Dipropyltryptamine) .  
134        70. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine) .  
135        71. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine) .  
136        72. DOI (4-Iodo-2,5-dimethoxyamphetamine) .  
137        73. DOC (4-Chloro-2,5-dimethoxyamphetamine) .  
138        74. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine) .  
139        75. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine) .  
140        76. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine) .  
141        77. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine) .  
142        78. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine) .  
143        79. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine) .  
144        80. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine) .  
145        81. Butylone (3,4-Methylenedioxy-alpha-  
146        methylaminobutyrophenone) .  
147        82. Ethcathinone.  
148        83. Ethylone (3,4-Methylenedioxy-N-ethylcathinone) .  
149        84. Naphyrone (Naphthylpyrovalerone) .  
150        85. Dimethylone (3,4-Methylenedioxy-N,N-

CS/HB 1345

2021

151 dimethylcathinone) .  
152 86. 3,4-Methylenedioxy-N,N-diethylcathinone.  
153 87. 3,4-Methylenedioxy-propiophenone.  
154 88. 3,4-Methylenedioxy-alpha-bromopropiophenone.  
155 89. 3,4-Methylenedioxy-propiophenone-2-oxime.  
156 90. 3,4-Methylenedioxy-N-acetylcatinone.  
157 91. 3,4-Methylenedioxy-N-acetymethcathinone.  
158 92. 3,4-Methylenedioxy-N-acetylethcathinone.  
159 93. Bromomethcathinone.  
160 94. Buphedrone (alpha-Methylamino-butyrophenone) .  
161 95. Eutylone (3,4-Methylenedioxy-alpha-  
162 ethylaminobutyrophenone) .  
163 96. Dimethylcathinone.  
164 97. Dimethylmethcathinone.  
165 98. Pentylone (3,4-Methylenedioxy-alpha-  
166 methylaminovalerophenone) .  
167 99. MDPPP (3,4-Methylenedioxy-alpha-  
168 pyrrolidinopropiophenone) .  
169 100. MDPBP (3,4-Methylenedioxy-alpha-  
170 pyrrolidinobutyrophenone) .  
171 101. MOPPP (Methoxy-alpha-pyrrolidinopropiophenone) .  
172 102. MPH<sub>P</sub> (Methyl-alpha-pyrrolidinohexanophenone) .  
173 103. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP  
174 (Benocyclidine) .  
175 104. F-MABP (Fluoromethylaminobutyrophenone) .

- 176        105. MeO-PBP (Methoxypyrrolidinobutyrophenone) .  
177        106. Et-PBP (Ethylpyrrolidinobutyrophenone) .  
178        107. 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone) .  
179        108. Me-EABP (Methylethylaminobutyrophenone) .  
180        109. Etizolam.  
181        110. PPP (Pyrrolidinopropiophenone) .  
182        111. PBP (Pyrrolidinobutyrophenone) .  
183        112. PVP (Pyrrolidinovalerophenone) or  
184 (Pyrrolidinopentiophenone) .  
185        113. MPPP (Methyl-alpha-pyrrolidinopropiophenone) .  
186        114. JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole) .  
187        115. JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole) .  
188        116. JWH-019 (1-Hexyl-3-(1-naphthoyl)indole) .  
189        117. JWH-020 (1-Heptyl-3-(1-naphthoyl)indole) .  
190        118. JWH-072 (1-Propyl-3-(1-naphthoyl)indole) .  
191        119. JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole) .  
192        120. JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole) .  
193        121. JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-  
194 methylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene) .  
195        122. JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole) .  
196        123. JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole) .  
197        124. JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole) .  
198        125. JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole) .  
199        126. JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole) .  
200        127. JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole) .

CS/HB 1345

2021

- 201        128. JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
- 202        129. JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).
- 203        130. HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-
- 204        (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-
- 205        ol).
- 206        131. HU-308 [(1R,2R,5R)-2-[2,6-Dimethoxy-4-(2-
- 207        methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-
- 208        enyl] methanol).
- 209        132. HU-331 (3-Hydroxy-2-[(1R,6R)-3-methyl-6-(1-
- 210        methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-
- 211        1,4-dione).
- 212        133. CB-13 (4-Pentyloxy-1-(1-naphthoyl)naphthalene).
- 213        134. CB-25 (N-Cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)-
- 214        undecanamide).
- 215        135. CB-52 (N-Cyclopropyl-11-(2-hexyl-5-hydroxyphenoxy)-
- 216        undecanamide).
- 217        136. CP 55,940 (2-[3-Hydroxy-6-propanol-cyclohexyl]-5-(2-
- 218        methyloctan-2-yl)phenol).
- 219        137. AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).
- 220        138. AM-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indole).
- 221        139. RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).
- 222        140. RCS-8 (1-(2-Cyclohexylethyl)-3-(2-
- 223        methoxyphenylacetyl)indole).
- 224        141. WIN55,212-2 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4-
- 225        morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-

CS/HB 1345

2021

226 naphthalenylmethanone) .  
227 142. WIN55,212-3 ((3S)-2,3-Dihydro-5-methyl-3-(4-  
228 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-  
229 naphthalenylmethanone) .  
230 143. Pentedrone (alpha-Methylaminovalerophenone) .  
231 144. Fluoroamphetamine.  
232 145. Fluoromethamphetamine.  
233 146. Methoxetamine.  
234 147. Methiopropamine.  
235 148. Methylbuphedrone (Methyl-alpha-  
236 methylaminobutyrophenone) .  
237 149. APB ((2-Aminopropyl)benzofuran) .  
238 150. APDB ((2-Aminopropyl)-2,3-dihydrobenzofuran) .  
239 151. UR-144 (1-Pentyl-3-(2,2,3,3-  
240 tetramethylcyclopropanoyl)indole) .  
241 152. XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3-  
242 tetramethylcyclopropanoyl)indole) .  
243 153. Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3-  
244 tetramethylcyclopropanoyl)indole) .  
245 154. AKB48 (N-Adamant-1-yl 1-pentylindazole-3-  
246 carboxamide) .  
247 155. AM-2233(1-[ (N-Methyl-2-piperidinyl)methyl]-3-(2-  
248 iodobenzoyl)indole) .  
249 156. STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3-  
250 carboxamide) .

CS/HB 1345

2021

- 251        157. URB-597 ((3'-(Aminocarbonyl)[1,1'-biphenyl]-3-yl)-  
252 cyclohexylcarbamate).
- 253        158. URB-602 ([1,1'-Biphenyl]-3-yl-carbamic acid,  
254 cyclohexyl ester).
- 255        159. URB-754 (6-Methyl-2-[(4-methylphenyl)amino]-1-  
256 benzoxazin-4-one).
- 257        160. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
- 258        161. 2C-H (2,5-Dimethoxyphenethylamine).
- 259        162. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
- 260        163. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
- 261        164. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2-  
262 methoxybenzyl)phenethylamine].
- 263        165. MDMA (3,4-Methylenedioxymethamphetamine).
- 264        166. PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate).
- 265        167. Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3-  
266 carboxylate).
- 267        168. BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3-  
268 carboxylate).
- 269        169. Fluoro AKB48 (N-Adamant-1-yl 1-  
270 (fluoropentyl)indazole-3-carboxamide).
- 271        170. AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-  
272 pentylindazole-3-carboxamide).
- 273        171. AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-  
274 (4-fluorobenzyl)indazole-3-carboxamide).
- 275        172. ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-

CS/HB 1345

2021

276 1-pentylindazole-3-carboxamide).  
277 173. Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-  
278 yl)-1-(fluoropentyl)indole-3-carboxamide).  
279 174. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2-  
280 methoxybenzyl)phenethylamine].  
281 175. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2-  
282 methoxybenzyl)phenethylamine].  
283 176. AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-  
284 (cyclohexylmethyl)indazole-3-carboxamide).  
285 177. FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3-  
286 carboxylate).  
287 178. Fluoro-NNEI (N-Naphthalen-1-yl 1-  
288 (fluoropentyl)indole-3-carboxamide).  
289 179. Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-  
290 (fluoropentyl)indazole-3-carboxamide).  
291 180. THJ-2201 (1-(5-Fluoropentyl)-3-(1-  
292 naphthoyl)indazole).  
293 181. AM-855 ((4aR,12bR)-8-Hexyl-2,5,5-trimethyl-  
294 1,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol).  
295 182. AM-905 ((6aR,9R,10aR)-3-[(E)-Hept-1-enyl]-9-  
296 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-  
297 hexahydrobenzo[c]chromen-1-ol).  
298 183. AM-906 ((6aR,9R,10aR)-3-[(Z)-Hept-1-enyl]-9-  
299 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-  
300 hexahydrobenzo[c]chromen-1-ol).

CS/HB 1345

2021

301        184. AM-2389 ((6aR,9R,10aR)-3-(1-Hexyl-cyclobut-1-yl)-  
302        6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9  
303        diol).

304        185. HU-243 ((6aR,8S,9S,10aR)-9-(Hydroxymethyl)-6,6-  
305        dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a-  
306        tetrahydro-6aH-benzo[c]chromen-1-ol).

307        186. HU-336 ((6aR,10aR)-6,6,9-Trimethyl-3-pentyl-  
308        6a,7,10,10a-tetrahydro-1H-benzo[c]chromene-1,4(6H)-dione).

309        187. MAPB ((2-Methylaminopropyl)benzofuran).

310        188. 5-IT (2-(1H-Indol-5-yl)-1-methyl-ethylamine).

311        189. 6-IT (2-(1H-Indol-6-yl)-1-methyl-ethylamine).

312        190. Synthetic Cannabinoids.—Unless specifically excepted  
313 or unless listed in another schedule or contained within a  
314 pharmaceutical product approved by the United States Food and  
315 Drug Administration, any material, compound, mixture, or  
316 preparation that contains any quantity of a synthetic  
317 cannabinoid found to be in any of the following chemical class  
318 descriptions, or homologues, nitrogen-heterocyclic analogs,  
319 isomers (including optical, positional, or geometric), esters,  
320 ethers, salts, and salts of homologues, nitrogen-heterocyclic  
321 analogs, isomers, esters, or ethers, whenever the existence of  
322 such homologues, nitrogen-heterocyclic analogs, isomers, esters,  
323 ethers, salts, and salts of isomers, esters, or ethers is  
324 possible within the specific chemical class or designation.  
325 Since nomenclature of these synthetically produced cannabinoids

CS/HB 1345

2021

326     is not internationally standardized and may continually evolve,  
327     these structures or the compounds of these structures shall be  
328     included under this subparagraph, regardless of their specific  
329     numerical designation of atomic positions covered, if it can be  
330     determined through a recognized method of scientific testing or  
331     analysis that the substance contains properties that fit within  
332     one or more of the following categories:

333         a. Tetrahydrocannabinols.—Any tetrahydrocannabinols  
334     naturally contained in a plant of the genus *Cannabis*, the  
335     synthetic equivalents of the substances contained in the plant  
336     or in the resinous extracts of the genus *Cannabis*, or synthetic  
337     substances, derivatives, and their isomers with similar chemical  
338     structure and pharmacological activity, including, but not  
339     limited to, Delta 9 tetrahydrocannabinols and their optical  
340     isomers, Delta 8 tetrahydrocannabinols and their optical  
341     isomers, Delta 6a,10a tetrahydrocannabinols and their optical  
342     isomers, or any compound containing a tetrahydrobenzo[c]chromene  
343     structure with substitution at either or both the 3-position or  
344     9-position, with or without substitution at the 1-position with  
345     hydroxyl or alkoxy groups, including, but not limited to:

346             (I) Tetrahydrocannabinol.

347             (II) HU-210 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-  
348             (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-  
349             ol).

350             (III) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-

CS/HB 1345

2021

351 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-  
352 ol).

353 (IV) JWH-051 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-  
354 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

355 (V) JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan-  
356 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

357 (VI) JWH-057 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methyloctan-  
358 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

359 (VII) JWH-359 ((6aR,10aR)-1-Methoxy-6,6,9-trimethyl-3-  
360 (2,3-dimethylpentan-2-yl)-6a,7,10,10a-  
361 tetrahydrobenzo[c]chromene).

362 (VIII) AM-087 ((6aR,10aR)-3-(2-Methyl-6-bromohex-2-yl)-  
363 6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).

364 (IX) AM-411 ((6aR,10aR)-3-(1-Adamantyl)-6,6,9-trimethyl-  
365 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).

366 (X) Parahexyl.

367 b. Naphthoylindoles, Naphthoylindazoles,  
368 Naphthoylcarbazoles, Naphthylmethylinidoles,  
369 Naphthylmethylinazoles, and Naphthylmethylicarbazoles.—Any  
370 compound containing a naphthoylindole, naphthoylindazole,  
371 naphthoylcarbazole, naphthylmethylinazole,  
372 naphthylmethylinazole, or naphthylmethylicarbazole structure,  
373 with or without substitution on the indole, indazole, or  
374 carbazole ring to any extent, whether or not substituted on the  
375 naphthyl ring to any extent, including, but not limited to:

CS/HB 1345

2021

376 (I) JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).  
377 (II) JWH-011 (1-(1-Methylhexyl)-2-methyl-3-(1-  
378 naphthoyl)indole).  
379 (III) JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).  
380 (IV) JWH-016 (1-Butyl-2-methyl-3-(1-naphthoyl)indole).  
381 (V) JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).  
382 (VI) JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).  
383 (VII) JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).  
384 (VIII) JWH-022 (1-(4-Pentenyl)-3-(1-naphthoyl)indole).  
385 (IX) JWH-071 (1-Ethyl-3-(1-naphthoyl)indole).  
386 (X) JWH-072 (1-Propyl-3-(1-naphthoyl)indole).  
387 (XI) JWH-073 (1-Butyl-3-(1-naphthoyl)indole).  
388 (XII) JWH-080 (1-Butyl-3-(4-methoxy-1-naphthoyl)indole).  
389 (XIII) JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).  
390 (XIV) JWH-098 (1-Pentyl-2-methyl-3-(4-methoxy-1-  
391 naphthoyl)indole).  
392 (XV) JWH-116 (1-Pentyl-2-ethyl-3-(1-naphthoyl)indole).  
393 (XVI) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).  
394 (XVII) JWH-149 (1-Pentyl-2-methyl-3-(4-methyl-1-  
395 naphthoyl)indole).  
396 (XVIII) JWH-164 (1-Pentyl-3-(7-methoxy-1-  
397 naphthoyl)indole).  
398 (XIX) JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).  
399 (XX) JWH-180 (1-Propyl-3-(4-propyl-1-naphthoyl)indole).  
400 (XXI) JWH-182 (1-Pentyl-3-(4-propyl-1-naphthoyl)indole).

CS/HB 1345

2021

- 401           (XXII) JWH-184 (1-Pentyl-3-[ (4-methyl)-1-  
402 naphthylmethyl]indole).  
403           (XXIII) JWH-193 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methyl-1-  
404 naphthoyl)indole).  
405           (XXIV) JWH-198 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methoxy-1-  
406 naphthoyl)indole).  
407           (XXV) JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-  
408 naphthoyl)indole).  
409           (XXVI) JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).  
410           (XXVII) JWH-387 (1-Pentyl-3-(4-bromo-1-naphthoyl)indole).  
411           (XXVIII) JWH-398 (1-Pentyl-3-(4-chloro-1-  
412 naphthoyl)indole).  
413           (XXIX) JWH-412 (1-Pentyl-3-(4-fluoro-1-naphthoyl)indole).  
414           (XXX) JWH-424 (1-Pentyl-3-(8-bromo-1-naphthoyl)indole).  
415           (XXXI) AM-1220 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(1-  
416 naphthoyl)indole).  
417           (XXXII) AM-1235 (1-(5-Fluoropentyl)-6-nitro-3-(1-  
418 naphthoyl)indole).  
419           (XXXIII) AM-2201 (1-(5-Fluoropentyl)-3-(1-  
420 naphthoyl)indole).  
421           (XXXIV) Chloro JWH-018 (1-(Chloropentyl)-3-(1-  
422 naphthoyl)indole).  
423           (XXXV) Bromo JWH-018 (1-(Bromopentyl)-3-(1-  
424 naphthoyl)indole).  
425           (XXXVI) AM-2232 (1-(4-Cyanobutyl)-3-(1-naphthoyl)indole).

CS/HB 1345

2021

- 426           (XXXVII) THJ-2201 (1-(5-Fluoropentyl)-3-(1-  
427 naphthoyl)indazole).
- 428           (XXXVIII) MAM-2201 (1-(5-Fluoropentyl)-3-(4-methyl-1-  
429 naphthoyl)indole).
- 430           (XXXIX) EAM-2201 (1-(5-Fluoropentyl)-3-(4-ethyl-1-  
431 naphthoyl)indole).
- 432           (XL) EG-018 (9-Pentyl-3-(1-naphthoyl)carbazole).
- 433           (XLI) EG-2201 (9-(5-Fluoropentyl)-3-(1-  
434 naphthoyl)carbazole).
- 435           c. Naphthoylpyrroles.—Any compound containing a  
436 naphthoylpyrrole structure, with or without substitution on the  
437 pyrrole ring to any extent, whether or not substituted on the  
438 naphthyl ring to any extent, including, but not limited to:
- 439           (I) JWH-030 (1-Pentyl-3-(1-naphthoyl)pyrrole).
- 440           (II) JWH-031 (1-Hexyl-3-(1-naphthoyl)pyrrole).
- 441           (III) JWH-145 (1-Pentyl-5-phenyl-3-(1-naphthoyl)pyrrole).
- 442           (IV) JWH-146 (1-Heptyl-5-phenyl-3-(1-naphthoyl)pyrrole).
- 443           (V) JWH-147 (1-Hexyl-5-phenyl-3-(1-naphthoyl)pyrrole).
- 444           (VI) JWH-307 (1-Pentyl-5-(2-fluorophenyl)-3-(1-  
445 naphthoyl)pyrrole).
- 446           (VII) JWH-309 (1-Pentyl-5-(1-naphthalenyl)-3-(1-  
447 naphthoyl)pyrrole).
- 448           (VIII) JWH-368 (1-Pentyl-5-(3-fluorophenyl)-3-(1-  
449 naphthoyl)pyrrole).
- 450           (IX) JWH-369 (1-Pentyl-5-(2-chlorophenyl)-3-(1-

CS/HB 1345

2021

451 naphthoyl)pyrrole).

452 (X) JWH-370 (1-Pentyl-5-(2-methylphenyl)-3-(1-  
453 naphthoyl)pyrrole).

454 d. Naphthylmethylenindenes.—Any compound containing a  
455 naphthylmethylenindene structure, with or without substitution  
456 at the 3-position of the indene ring to any extent, whether or  
457 not substituted on the naphthyl ring to any extent, including,  
458 but not limited to, JWH-176 (3-Pentyl-1-  
459 (naphthylmethylene)indene).

460 e. Phenylacetylindoles and Phenylacetylindazoles.—Any  
461 compound containing a phenylacetylindole or phenylacetylindazole  
462 structure, with or without substitution on the indole or  
463 indazole ring to any extent, whether or not substituted on the  
464 phenyl ring to any extent, including, but not limited to:

465 (I) JWH-167 (1-Pentyl-3-(phenylacetyl)indole).

466 (II) JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).

467 (III) JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).

468 (IV) JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).

469 (V) JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).

470 (VI) JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).

471 (VII) Cannabipiperidiethanone.

472 (VIII) RCS-8 (1-(2-Cyclohexylethyl)-3-(2-  
473 methoxyphenylacetyl)indole).

474 f. Cyclohexylphenols.—Any compound containing a  
475 cyclohexylphenol structure, with or without substitution at the

CS/HB 1345

2021

476 5-position of the phenolic ring to any extent, whether or not  
477 substituted on the cyclohexyl ring to any extent, including, but  
478 not limited to:

479 (I) CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2-  
480 yl)phenol).

481 (II) Cannabicyclohexanol (CP 47,497 dimethyloctyl (C8)  
482 homologue).

483 (III) CP-55,940 (2-(3-Hydroxy-6-propanol-cyclohexyl)-5-(2-  
484 methyloctan-2-yl)phenol).

485 g. Benzoylindoles and Benzoylindazoles.—Any compound  
486 containing a benzoylindole or benzoylindazole structure, with or  
487 without substitution on the indole or indazole ring to any  
488 extent, whether or not substituted on the phenyl ring to any  
489 extent, including, but not limited to:

490 (I) AM-679 (1-Pentyl-3-(2-iodobenzoyl)indole).

491 (II) AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).

492 (III) AM-1241 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-  
493 iodo-5-nitrobenzoyl)indole).

494 (IV) Pravadoline (1-[2-(4-Morpholinyl)ethyl]-2-methyl-3-  
495 (4-methoxybenzoyl)indole).

496 (V) AM-2233 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-  
497 iodo benzoyl)indole).

498 (VI) RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).

499 (VII) RCS-4 C4 homologue (1-Butyl-3-(4-  
500 methoxybenzoyl)indole).

CS/HB 1345

2021

501                 (VIII) AM-630 (1-[2-(4-Morpholinyl)ethyl]-2-methyl-6-iodo-  
502 3-(4-methoxybenzoyl)indole).

503                 h. Tetramethylcyclopropanoylindoles and  
504 Tetramethylcyclopropanoylindazoles.—Any compound containing a  
505 tetramethylcyclopropanoylindole or  
506 tetramethylcyclopropanoylindazole structure, with or without  
507 substitution on the indole or indazole ring to any extent,  
508 whether or not substituted on the tetramethylcyclopropyl group  
509 to any extent, including, but not limited to:

510                 (I) UR-144 (1-Pentyl-3-(2,2,3,3,-  
511 tetramethylcyclopropanoyl)indole).

512                 (II) XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3-  
513 tetramethylcyclopropanoyl)indole).

514                 (III) Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3-  
515 tetramethylcyclopropanoyl)indole).

516                 (IV) A-796,260 (1-[2-(4-Morpholinyl)ethyl]-3-(2,2,3,3-  
517 tetramethylcyclopropanoyl)indole).

518                 (V) A-834,735 (1-[4-(Tetrahydropyranyl)methyl]-3-(2,2,3,3-  
519 tetramethylcyclopropanoyl)indole).

520                 (VI) M-144 (1-(5-Fluoropentyl)-2-methyl-3-(2,2,3,3-  
521 tetramethylcyclopropanoyl)indole).

522                 (VII) FUB-144 (1-(4-Fluorobenzyl)-3-(2,2,3,3-  
523 tetramethylcyclopropanoyl)indole).

524                 (VIII) FAB-144 (1-(5-Fluoropentyl)-3-(2,2,3,3-  
525 tetramethylcyclopropanoyl)indazole).

CS/HB 1345

2021

526           (IX) XLR12 (1-(4,4,4-Trifluorobutyl)-3-(2,2,3,3-tetramethylcyclopropanoyl)indole).

527           (X) AB-005 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(2,2,3,3-tetramethylcyclopropanoyl)indole).

528           i. Adamantoylindoles, Adamantoylindazoles, Adamantylindole  
529 carboxamides, and Adamantylindazole carboxamides.—Any compound  
530 containing an adamantoyl indole, adamantoyl indazole, adamantyl  
531 indole carboxamide, or adamantyl indazole carboxamide structure,  
532 with or without substitution on the indole or indazole ring to  
533 any extent, whether or not substituted on the adamantyl ring to  
534 any extent, including, but not limited to:

535           (I) AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).

536           (II) Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole-3-carboxamide).

537           (III) STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3-carboxamide).

538           (IV) AM-1248 (1-(1-Methylpiperidine)methyl-3-(1-adamantoyl)indole).

539           (V) AB-001 (1-Pentyl-3-(1-adamantoyl)indole).

540           (VI) APICA (N-Adamant-1-yl 1-pentylindole-3-carboxamide).

541           (VII) Fluoro AB-001 (1-(Fluoropentyl)-3-(1-adamantoyl)indole).

542           j. Quinolinylindolecarboxylates,  
543 Quinolinylindazolecarboxylates, Quinolinylindolecarboxamides,  
544 and Quinolinylindazolecarboxamides.—Any compound containing a

CS/HB 1345

2021

551 quinolinylindole carboxylate, quinolinylindazole carboxylate,  
552 isoquinolinylindole carboxylate, isoquinolinylindazole  
553 carboxylate, quinolinylindole carboxamide, quinolinylindazole  
554 carboxamide, isoquinolinylindole carboxamide, or  
555 isoquinolinylindazole carboxamide structure, with or without  
556 substitution on the indole or indazole ring to any extent,  
557 whether or not substituted on the quinoline or isoquinoline ring  
558 to any extent, including, but not limited to:

559 (I) PB-22 (8-Quinolinyl 1-pentylinde-3-carboxylate).

560 (II) Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3-  
561 carboxylate).

562 (III) BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3-  
563 carboxylate).

564 (IV) FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3-  
565 carboxylate).

566 (V) NPB-22 (8-Quinolinyl 1-pentylinde-3-carboxylate).

567 (VI) Fluoro NPB-22 (8-Quinolinyl 1-(fluoropentyl)indazole-  
568 3-carboxylate).

569 (VII) FUB-NPB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indazole-  
570 3-carboxylate).

571 (VIII) THJ (8-Quinolinyl 1-pentylinde-3-carboxamide).

572 (IX) Fluoro THJ (8-Quinolinyl 1-(fluoropentyl)indazole-3-  
573 carboxamide).

574 k. Naphthylindolecarboxylates and  
575 Naphthylindazolecarboxylates.—Any compound containing a

CS/HB 1345

2021

576 naphthylinole carboxylate or naphthylinazole carboxylate  
577 structure, with or without substitution on the indole or  
578 indazole ring to any extent, whether or not substituted on the  
579 naphthyl ring to any extent, including, but not limited to:

580 (I) NM-2201 (1-Naphthalenyl 1-(5-fluoropentyl)indole-3-  
581 carboxylate).

582 (II) SDB-005 (1-Naphthalenyl 1-pentylindazole-3-  
583 carboxylate).

584 (III) Fluoro SDB-005 (1-Naphthalenyl 1-  
585 (fluoropentyl)indazole-3-carboxylate).

586 (IV) FDU-PB-22 (1-Naphthalenyl 1-(4-fluorobenzyl)indole-3-  
587 carboxylate).

588 (V) 3-CAF (2-Naphthalenyl 1-(2-fluorophenyl)indazole-3-  
589 carboxylate).

590 1. Naphthylinole carboxamides and Naphthylinazole  
591 carboxamides.—Any compound containing a naphthylinole  
592 carboxamide or naphthylinazole carboxamide structure, with or  
593 without substitution on the indole or indazole ring to any  
594 extent, whether or not substituted on the naphthyl ring to any  
595 extent, including, but not limited to:

596 (I) NNEI (N-Naphthalen-1-yl 1-pentylindole-3-carboxamide).

597 (II) Fluoro-NNEI (N-Naphthalen-1-yl 1-  
598 (fluoropentyl)indole-3-carboxamide).

599 (III) Chloro-NNEI (N-Naphthalen-1-yl 1-  
600 (chloropentyl)indole-3-carboxamide).

CS/HB 1345

2021

601           (IV) MN-18 (N-Naphthalen-1-yl 1-pentylindazole-3-  
602 carboxamide).

603           (V) Fluoro MN-18 (N-Naphthalen-1-yl 1-  
604 (fluoropentyl)indazole-3-carboxamide).

605           m. Alkylcarbonyl indole carboxamides, Alkylcarbonyl  
606 indazole carboxamides, Alkylcarbonyl indole carboxylates, and  
607 Alkylcarbonyl indazole carboxylates.—Any compound containing an  
608 alkylcarbonyl group, including 1-amino-3-methyl-1-oxobutan-2-yl,  
609 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-amino-1-oxo-3-  
610 phenylpropan-2-yl, 1-methoxy-1-oxo-3-phenylpropan-2-yl, with an  
611 indole carboxamide, indazole carboxamide, indole carboxylate, or  
612 indazole carboxylate, with or without substitution on the indole  
613 or indazole ring to any extent, whether or not substituted on  
614 the alkylcarbonyl group to any extent, including, but not  
615 limited to:

616           (I) ADBICA, (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-  
617 pentylindole-3-carboxamide).

618           (II) Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-  
619 yl)-1-(fluoropentyl)indole-3-carboxamide).

620           (III) Fluoro ABICA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-  
621 1-(fluoropentyl)indole-3-carboxamide).

622           (IV) AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-  
623 pentylindazole-3-carboxamide).

624           (V) Fluoro AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-  
625 yl)-1-(fluoropentyl)indazole-3-carboxamide).

CS/HB 1345

2021

626           (VI) ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-  
627 1-pentylindeazole-3-carboxamide).  
628           (VII) Fluoro ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-  
629 oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide).  
630           (VIII) AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-  
631 1-(4-fluorobenzyl)indazole-3-carboxamide).  
632           (IX) ADB-FUBINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-  
633 yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).  
634           (X) AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-  
635 (cyclohexylmethyl)indazole-3-carboxamide).  
636           (XI) MA-CHMINACA (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-  
637 1-(cyclohexylmethyl)indazole-3-carboxamide).  
638           (XII) MAB-CHMINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-  
639 yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).  
640           (XIII) AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-  
641 pentylindeazole-3-carboxamide).  
642           (XIV) Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-  
643 1-(fluoropentyl)indazole-3-carboxamide).  
644           (XV) FUB-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(4-  
645 fluorobenzyl)indazole-3-carboxamide).  
646           (XVI) MDMB-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-  
647 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).  
648           (XVII) MDMB-FUBINACA (N-(1-Methoxy-3,3-dimethyl-1-  
649 oxobutan-2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).  
650           (XVIII) MDMB-CHMICA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-

CS/HB 1345

2021

651 2-yl)-1-(cyclohexylmethyl)indole-3-carboxamide).  
652 (XIX) PX-1 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-  
653 fluoropentyl)indole-3-carboxamide).  
654 (XX) PX-2 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-  
655 fluoropentyl)indazole-3-carboxamide).  
656 (XXI) PX-3 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-  
657 (cyclohexylmethyl)indazole-3-carboxamide).  
658 (XXII) PX-4 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(4-  
659 fluorobenzyl)indazole-3-carboxamide).  
660 (XXIII) MO-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-  
661 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxylate).  
662 n. Cumylindolecarboxamides and Cumylindazolecarboxamides.—  
663 Any compound containing a N-(2-phenylpropan-2-yl) indole  
664 carboxamide or N-(2-phenylpropan-2-yl) indazole carboxamide  
665 structure, with or without substitution on the indole or  
666 indazole ring to any extent, whether or not substituted on the  
667 phenyl ring of the cumyl group to any extent, including, but not  
668 limited to:  
669 (I) CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-pentylindole-3-  
670 carboxamide).  
671 (II) Fluoro CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-  
672 (fluoropentyl)indole-3-carboxamide).  
673 o. Other Synthetic Cannabinoids.—Any material, compound,  
674 mixture, or preparation that contains any quantity of a  
675 Synthetic Cannabinoid, as described in sub-subparagraphs a.-n.:

CS/HB 1345

2021

676       (I) With or without modification or replacement of a  
677 carbonyl, carboxamide, alkylene, alkyl, or carboxylate linkage  
678 between either two core rings, or linkage between a core ring  
679 and group structure, with or without the addition of a carbon or  
680 replacement of a carbon;

681       (II) With or without replacement of a core ring or group  
682 structure, whether or not substituted on the ring or group  
683 structures to any extent; and

684       (III) Is a cannabinoid receptor agonist, unless  
685 specifically excepted or unless listed in another schedule or  
686 contained within a pharmaceutical product approved by the United  
687 States Food and Drug Administration.

688       191. Substituted Cathinones.—Unless specifically excepted,  
689 listed in another schedule, or contained within a pharmaceutical  
690 product approved by the United States Food and Drug  
691 Administration, any material, compound, mixture, or preparation,  
692 including its salts, isomers, esters, or ethers, and salts of  
693 isomers, esters, or ethers, whenever the existence of such salts  
694 is possible within any of the following specific chemical  
695 designations:

696       a. Any compound containing a 2-amino-1-phenyl-1-propanone  
697 structure;

698       b. Any compound containing a 2-amino-1-naphthyl-1-  
699 propanone structure; or

700       c. Any compound containing a 2-amino-1-thiophenyl-1-

CS/HB 1345

2021

701 propanone structure,

702  
703 whether or not the compound is further modified:

704 (I) With or without substitution on the ring system to any  
705 extent with alkyl, alkylthio, thio, fused alkylenedioxy, alkoxy,  
706 haloalkyl, hydroxyl, nitro, fused furan, fused benzofuran, fused  
707 dihydrofuran, fused tetrahydropyran, fused alkyl ring, or halide  
708 substituents;

709 (II) With or without substitution at the 3-propanone  
710 position with an alkyl substituent or removal of the methyl  
711 group at the 3-propanone position;

712 (III) With or without substitution at the 2-amino nitrogen  
713 atom with alkyl, dialkyl, acetyl, or benzyl groups, whether or  
714 not further substituted in the ring system; or

715 (IV) With or without inclusion of the 2-amino nitrogen  
716 atom in a cyclic structure, including, but not limited to:

717 (A) Methcathinone.

718 (B) Ethcathinone.

719 (C) Methylone (3,4-Methylenedioxymethcathinone).

720 (D) 2,3-Methylenedioxymethcathinone.

721 (E) MDPV (3,4-Methylenedioxypyrovalerone).

722 (F) Methylmethcathinone.

723 (G) Methoxymethcathinone.

724 (H) Fluoromethcathinone.

725 (I) Methylethcathinone.

CS/HB 1345

2021

- 726           (J) Butylone (3,4-Methylenedioxy-alpha-  
727 methylaminobutyrophenone) .
- 728           (K) Ethylone (3,4-Methylenedioxy-N-ethylcathinone) .
- 729           (L) BMDP (3,4-Methylenedioxy-N-benzylcathinone) .
- 730           (M) Naphyrone (Naphthylpyrovalerone) .
- 731           (N) Bromomethcathinone.
- 732           (O) Buphedrone (alpha-Methylaminobutyrophenone) .
- 733           (P) Eutylone (3,4-Methylenedioxy-alpha-  
734 ethylaminobutyrophenone) .
- 735           (Q) Dimethylcathinone.
- 736           (R) Dimethylmethcathinone.
- 737           (S) Pentylylone (3,4-Methylenedioxy-alpha-  
738 methylaminovalerophenone) .
- 739           (T) Pentedrone (alpha-Methylaminovalerophenone) .
- 740           (U) MDPPP (3,4-Methylenedioxy-alpha-  
741 pyrrolidinopropiophenone) .
- 742           (V) MDPBP (3,4-Methylenedioxy-alpha-  
743 pyrrolidinobutyrophenone) .
- 744           (W) MPPP (Methyl-alpha-pyrrolidinopropiophenone) .
- 745           (X) PPP (Pyrrolidinopropiophenone) .
- 746           (Y) PVP (Pyrrolidinovalerophenone) or  
747 (Pyrrolidinopentiophenone) .
- 748           (Z) MOPPP (Methoxy-alpha-pyrrolidinopropiophenone) .
- 749           (AA) MPHPh (Methyl-alpha-pyrrolidinohexanophenone) .
- 750           (BB) F-MABP (Fluoromethylaminobutyrophenone) .

751           (CC) Me-EABP (Methylethylaminobutyrophenone) .  
752           (DD) PBP (Pyrrolidinobutyrophenone) .  
753           (EE) MeO-PBP (Methoxypyrrrolidinobutyrophenone) .  
754           (FF) Et-PBP (Ethylpyrrolidinobutyrophenone) .  
755           (GG) 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone) .  
756           (HH) Dimethylone (3,4-Methylenedioxy-N,N-  
757 dimethylcathinone) .  
758           (II) 3,4-Methylenedioxy-N,N-diethylcathinone.  
759           (JJ) 3,4-Methylenedioxy-N-acetylcatinone.  
760           (KK) 3,4-Methylenedioxy-N-acetylmethcathinone.  
761           (LL) 3,4-Methylenedioxy-N-acetylethcathinone.  
762           (MM) Methylbuphedrone (Methyl-alpha-  
763 methylaminobutyrophenone) .  
764           (NN) Methyl-alpha-methylaminohexanophenone.  
765           (OO) N-Ethyl-N-methylcathinone.  
766           (PP) PHP (Pyrrolidinohexanophenone) .  
767           (QQ) PV8 (Pyrrolidinoheptanophenone) .  
768           (RR) Chloromethcathinone.  
769           (SS) 4-Bromo-2,5-dimethoxy-alpha-aminoacetophenone.  
770           192. Substituted Phenethylamines.—Unless specifically  
771 excepted or unless listed in another schedule, or contained  
772 within a pharmaceutical product approved by the United States  
773 Food and Drug Administration, any material, compound, mixture,  
774 or preparation, including its salts, isomers, esters, or ethers,  
775 and salts of isomers, esters, or ethers, whenever the existence

CS/HB 1345

2021

776 of such salts is possible within any of the following specific  
777 chemical designations, any compound containing a phenethylamine  
778 structure, without a beta-keto group, and without a benzyl group  
779 attached to the amine group, whether or not the compound is  
780 further modified with or without substitution on the phenyl ring  
781 to any extent with alkyl, alkylthio, nitro, alkoxy, thio,  
782 halide, fused alkyleneoxy, fused furan, fused benzofuran,  
783 fused dihydrofuran, or fused tetrahydropyran substituents,  
784 whether or not further substituted on a ring to any extent, with  
785 or without substitution at the alpha or beta position by any  
786 alkyl substituent, with or without substitution at the nitrogen  
787 atom, and with or without inclusion of the 2-amino nitrogen atom  
788 in a cyclic structure, including, but not limited to:

- 789 a. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine) .
- 790 b. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine) .
- 791 c. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine) .
- 792 d. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine) .
- 793 e. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine) .
- 794 f. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine) .
- 795 g. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine) .
- 796 h. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine) .
- 797 i. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine) .
- 798 j. 2C-H (2,5-Dimethoxyphenethylamine) .
- 799 k. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine) .
- 800 l. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine) .

- 801       m. MDMA (3,4-Methylenedioxymethamphetamine).  
802       n. MBDB (Methylbenzodioxolylbutanamine) or (3,4-  
803       Methylenedioxy-N-methylbutanamine).  
804       o. MDA (3,4-Methylenedioxymphetamine).  
805       p. 2,5-Dimethoxyamphetamine.  
806       q. Fluoroamphetamine.  
807       r. Fluoromethamphetamine.  
808       s. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).  
809       t. DOB (4-Bromo-2,5-dimethoxyamphetamine).  
810       u. DOC (4-Chloro-2,5-dimethoxyamphetamine).  
811       v. DOET (4-Ethyl-2,5-dimethoxyamphetamine).  
812       w. DOI (4-Iodo-2,5-dimethoxyamphetamine).  
813       x. DOM (4-Methyl-2,5-dimethoxyamphetamine).  
814       y. PMA (4-Methoxyamphetamine).  
815       z. N-Ethylamphetamine.  
816       aa. 3,4-Methylenedioxy-N-hydroxyamphetamine.  
817       bb. 5-Methoxy-3,4-methylenedioxymphetamine.  
818       cc. PMMA (4-Methoxymethamphetamine).  
819       dd. N,N-Dimethylamphetamine.  
820       ee. 3,4,5-Trimethoxyamphetamine.  
821       ff. 4-APB (4-(2-Aminopropyl)benzofuran).  
822       gg. 5-APB (5-(2-Aminopropyl)benzofuran).  
823       hh. 6-APB (6-(2-Aminopropyl)benzofuran).  
824       ii. 7-APB (7-(2-Aminopropyl)benzofuran).  
825       jj. 4-APDB (4-(2-Aminopropyl)-2,3-dihydrobenzofuran).

826       kk. 5-APDB (5-(2-Aminopropyl)-2,3-dihydrobenzofuran).  
827       ll. 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran).  
828       mm. 7-APDB (7-(2-Aminopropyl)-2,3-dihydrobenzofuran).  
829       nn. 4-MAPB (4-(2-Methylaminopropyl)benzofuran).  
830       oo. 5-MAPB (5-(2-Methylaminopropyl)benzofuran).  
831       pp. 6-MAPB (6-(2-Methylaminopropyl)benzofuran).  
832       qq. 7-MAPB (7-(2-Methylaminopropyl)benzofuran).  
833       rr. 5-EAPB (5-(2-Ethylaminopropyl)benzofuran).  
834       ss. 5-MAPDB (5-(2-Methylaminopropyl)-2,3-  
835 dihydrobenzofuran),

836  
837 which does not include phenethylamine, mescaline as described in  
838 subparagraph 20., substituted cathinones as described in  
839 subparagraph 191., N-Benzyl phenethylamine compounds as  
840 described in subparagraph 193., or methamphetamine as described  
841 in subparagraph (2)(c)5.

842       193. N-Benzyl Phenethylamine Compounds.—Unless  
843 specifically excepted or unless listed in another schedule, or  
844 contained within a pharmaceutical product approved by the United  
845 States Food and Drug Administration, any material, compound,  
846 mixture, or preparation, including its salts, isomers, esters,  
847 or ethers, and salts of isomers, esters, or ethers, whenever the  
848 existence of such salts is possible within any of the following  
849 specific chemical designations, any compound containing a  
850 phenethylamine structure without a beta-keto group, with

CS/HB 1345

2021

851 substitution on the nitrogen atom of the amino group with a  
852 benzyl substituent, with or without substitution on the phenyl  
853 or benzyl ring to any extent with alkyl, alkoxy, thio,  
854 alkylthio, halide, fused alkylenedioxy, fused furan, fused  
855 benzofuran, or fused tetrahydropyran substituents, whether or  
856 not further substituted on a ring to any extent, with or without  
857 substitution at the alpha position by any alkyl substituent,  
858 including, but not limited to:

859       a. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2-  
860 methoxybenzyl)phenethylamine].

861       b. 25B-NBOH (4-Bromo-2,5-dimethoxy-[N-(2-  
862 hydroxybenzyl)phenethylamine].

863       c. 25B-NBF (4-Bromo-2,5-dimethoxy-[N-(2-  
864 fluorobenzyl)phenethylamine].

865       d. 25B-NBMD (4-Bromo-2,5-dimethoxy-[N-(2,3-  
866 methylenedioxybenzyl)phenethylamine].

867       e. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2-  
868 methoxybenzyl)phenethylamine].

869       f. 25I-NBOH (4-Iodo-2,5-dimethoxy-[N-(2-  
870 hydroxybenzyl)phenethylamine].

871       g. 25I-NBF (4-Iodo-2,5-dimethoxy-[N-(2-  
872 fluorobenzyl)phenethylamine].

873       h. 25I-NBMD (4-Iodo-2,5-dimethoxy-[N-(2,3-  
874 methylenedioxybenzyl)phenethylamine].

875       i. 25T2-NBOMe (4-Methylthio-2,5-dimethoxy-[N-(2-

CS/HB 1345

2021

876 methoxybenzyl) ]phenethylamine) .  
877       j. 25T4-NBOMe (4-Isopropylthio-2,5-dimethoxy-[N-(2-  
878 methoxybenzyl) ]phenethylamine) .  
879       k. 25T7-NBOMe (4-(n)-Propylthio-2,5-dimethoxy-[N-(2-  
880 methoxybenzyl) ]phenethylamine) .  
881       l. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2-  
882 methoxybenzyl) ]phenethylamine) .  
883       m. 25C-NBOH (4-Chloro-2,5-dimethoxy-[N-(2-  
884 hydroxybenzyl) ]phenethylamine) .  
885       n. 25C-NBF (4-Chloro-2,5-dimethoxy-[N-(2-  
886 fluorobenzyl) ]phenethylamine) .  
887       o. 25C-NBMD (4-Chloro-2,5-dimethoxy-[N-(2,3-  
888 methylenedioxybenzyl) ]phenethylamine) .  
889       p. 25H-NBOMe (2,5-Dimethoxy-[N-(2-  
890 methoxybenzyl) ]phenethylamine) .  
891       q. 25H-NBOH (2,5-Dimethoxy-[N-(2-  
892 hydroxybenzyl) ]phenethylamine) .  
893       r. 25H-NBF (2,5-Dimethoxy-[N-(2-  
894 fluorobenzyl) ]phenethylamine) .  
895       s. 25D-NBOMe (4-Methyl-2,5-dimethoxy-[N-(2-  
896 methoxybenzyl) ]phenethylamine) ,  
897  
898 which does not include substituted cathinones as described in  
899 subparagraph 191.  
900       194. Substituted Tryptamines.—Unless specifically excepted

CS/HB 1345

2021

901 or unless listed in another schedule, or contained within a  
902 pharmaceutical product approved by the United States Food and  
903 Drug Administration, any material, compound, mixture, or  
904 preparation containing a 2-(1H-indol-3-yl)ethanamine, for  
905 example tryptamine, structure with or without mono- or di-  
906 substitution of the amine nitrogen with alkyl or alkenyl groups,  
907 or by inclusion of the amino nitrogen atom in a cyclic  
908 structure, whether or not substituted at the alpha position with  
909 an alkyl group, whether or not substituted on the indole ring to  
910 any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy  
911 groups, including, but not limited to:

912     a. Alpha-Ethyltryptamine.  
913     b. Bufotenine.  
914     c. DET (Diethyltryptamine).  
915     d. DMT (Dimethyltryptamine).  
916     e. MET (N-Methyl-N-ethyltryptamine).  
917     f. DALT (N,N-Diallyltryptamine).  
918     g. EiPT (N-Ethyl-N-isopropyltryptamine).  
919     h. MiPT (N-Methyl-N-isopropyltryptamine).  
920     i. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).  
921     j. 5-Hydroxy-N-methyltryptamine.  
922     k. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).  
923     l. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).  
924     m. Methyltryptamine.  
925     n. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).

- 926       o. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).  
927       p. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).  
928       q. DiPT (N,N-Diisopropyltryptamine).  
929       r. DPT (N,N-Dipropyltryptamine).  
930       s. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).  
931       t. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).  
932       u. 4-AcO-DMT (4-Acetoxy-N,N-dimethyltryptamine).  
933       v. 4-AcO-DiPT (4-Acetoxy-N,N-diisopropyltryptamine).  
934       w. 4-Hydroxy-DET (4-Hydroxy-N,N-diethyltryptamine).  
935       x. 4-Hydroxy-MET (4-Hydroxy-N-methyl-N-ethyltryptamine).  
936       y. 4-Hydroxy-MiPT (4-Hydroxy-N-methyl-N-  
937 isopropyltryptamine).  
938       z. Methyl-alpha-ethyltryptamine.  
939       aa. Bromo-DALT (Bromo-N,N-diallyltryptamine),  
940  
941 which does not include tryptamine, psilocyn as described in  
942 subparagraph 34., or psilocybin as described in subparagraph 33.

943       195. Substituted Phenylcyclohexylamines.—Unless  
944 specifically excepted or unless listed in another schedule, or  
945 contained within a pharmaceutical product approved by the United  
946 States Food and Drug Administration, any material, compound,  
947 mixture, or preparation containing a phenylcyclohexylamine  
948 structure, with or without any substitution on the phenyl ring,  
949 any substitution on the cyclohexyl ring, any replacement of the  
950 phenyl ring with a thiophenyl or benzothiophenyl ring, with or

CS/HB 1345

2021

951 without substitution on the amine with alkyl, dialkyl, or alkoxy  
952 substituents, inclusion of the nitrogen in a cyclic structure,  
953 or any combination of the above, including, but not limited to:  
954       a. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP  
955 (Benocyclidine).  
956       b. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine analog  
957 of phencyclidine).  
958       c. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine  
959 analog of phencyclidine).  
960       d. PCPr (Phenylcyclohexylpropylamine).  
961       e. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine) (Thiophene  
962 analog of phencyclidine).  
963       f. PCEEA (Phenylcyclohexyl(ethoxyethylamine)).  
964       g. PCMPA (Phenylcyclohexyl(methoxypropylamine)).  
965       h. Methoxetamine.  
966       i. 3-Methoxy-PCE ((3-Methoxyphenyl)cyclohexylethylamine).  
967       j. Bromo-PCP ((Bromophenyl)cyclohexylpiperidine).  
968       k. Chloro-PCP ((Chlorophenyl)cyclohexylpiperidine).  
969       l. Fluoro-PCP ((Fluorophenyl)cyclohexylpiperidine).  
970       m. Hydroxy-PCP ((Hydroxyphenyl)cyclohexylpiperidine).  
971       n. Methoxy-PCP ((Methoxyphenyl)cyclohexylpiperidine).  
972       o. Methyl-PCP ((Methylphenyl)cyclohexylpiperidine).  
973       p. Nitro-PCP ((Nitrophenyl)cyclohexylpiperidine).  
974       q. Oxo-PCP ((Oxophenyl)cyclohexylpiperidine).  
975       r. Amino-PCP ((Aminophenyl)cyclohexylpiperidine).

CS/HB 1345

2021

976        196. W-15, 4-chloro-N-[1-(2-phenylethyl)-2-piperidinylidene]-benzenesulfonamide.

977        197. W-18, 4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2-piperidinylidene]-benzenesulfonamide.

980        198. AH-7921, 3,4-dichloro-N-[1-(dimethylamino)cyclohexyl]methyl]-benzamide.

982        199. U47700, trans-3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzamide.

984        200. MT-45, 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine, dihydrochloride.

986        (5) SCHEDULE V.—A substance, compound, mixture, or preparation of a substance in Schedule V has a low potential for abuse relative to the substances in Schedule IV and has a currently accepted medical use in treatment in the United States, and abuse of such compound, mixture, or preparation may lead to limited physical or psychological dependence relative to the substances in Schedule IV.

993        ~~(d) A drug product in finished dosage formulation that has been approved by the United States Food and Drug Administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.~~

999        Section 2. Subsection (3) of section 893.02, Florida Statutes, is amended to read:

CS/HB 1345

2021

1001        893.02 Definitions.—The following words and phrases as  
1002 used in this chapter shall have the following meanings, unless  
1003 the context otherwise requires:

1004        (3) "Cannabis" means all parts of any plant of the genus  
1005 Cannabis, whether growing or not; the seeds thereof; the resin  
1006 extracted from any part of the plant; and every compound,  
1007 manufacture, salt, derivative, mixture, or preparation of the  
1008 plant or its seeds or resin. The term does not include  
1009 "marijuana," as defined in s. 381.986, if manufactured,  
1010 possessed, sold, purchased, delivered, distributed, or  
1011 dispensed, in conformance with s. 381.986. The term does not  
1012 include hemp as defined in s. 581.217 or industrial hemp as  
1013 defined in s. 1004.4473. ~~The term does not include a drug~~  
1014 ~~product described in s. 893.03(5)(d).~~

1015        Section 3. This act shall take effect upon becoming a law.